KALV – kalvista pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is now covered by analysts at Bank of America Co.. They set a "buy" rating and a $22.00 price target on the stock.
KalVista Appoints Jeb Ledell as Chief Operating Officer [Yahoo! Finance]
KalVista Appoints Jeb Ledell as Chief Operating Officer
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Form 8-K KalVista Pharmaceuticals For: Dec 16
Form 4 KalVista Pharmaceuticals For: Dec 06 Filed by: Palleiko Benjamin L
Form 8-K KalVista Pharmaceuticals For: Dec 05
Form 10-Q KalVista Pharmaceuticals For: Oct 31
Form 4 KalVista Pharmaceuticals For: Nov 22 Filed by: Audhya Paul K.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.